Working… Menu

A Study to Investigate BGB-3111 in Chinese Participants With B-cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03189524
Recruitment Status : Completed
First Posted : June 16, 2017
Last Update Posted : June 30, 2021
Information provided by (Responsible Party):

Brief Summary:

This phase I clinical study is to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of BTK inhibitor BGB-3111 in Chinese participants with B-cell lymphoma, by conducting in two stages, the first stage being the safety assessment of dose, and the second stage being the dose expansion.

Part I: Safety evaluation - according to the results of preclinical toxicological trials and the results of the phase I clinical study conducted in Australia and New Zealand, two regimens of BGB-3111 320 mg daily (160 mg twice daily (BID), administered in the morning and at night, or 320 mg QD) and "3+3" design is adopted for the assessment. The recommended dose and method of administration of phase II clinical study will be determined according to the Part I results.

Part II: Dose expansion - this stage is to further evaluate the preliminary anti-tumor effects of BGB-3111 in Chinese participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL), approximately 20 participants with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL) will be enrolled. The recommended Phase 2 dose will be used in the Part II.

Condition or disease Intervention/treatment Phase
B-cell Lymphoma Drug: BGB-3111 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics/ Pharmacodynamics of BTK Inhibitor BGB-3111 in Chinese Patients With B-cell Lymphoma
Actual Study Start Date : July 5, 2016
Actual Primary Completion Date : August 26, 2020
Actual Study Completion Date : August 26, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: BGB-3111
Two regimens of BGB-3111 320 mg daily (160 mg BID, administered in the morning and at night, or 320 mg QD) and "3+3" design is adopted for the study Part I to determine RP2D. The RP2D determined will be used in Part II to further evaluate the preliminary anti-tumor effects of BGB-3111 in Chinese subjects with follicular lymphoma (FL) or marginal zone lymphoma (MZL)
Drug: BGB-3111

Primary Outcome Measures :
  1. The safety and tolerability of BGB-3111 measured by the occurrence of adverse events and serious adverse events according to NCI-CTCAE4.03 grading criteria in Part I [ Time Frame: Up to 5 years ]
  2. The efficacy measured by overall response rate (ORR) in Part II [ Time Frame: Up to 5 years ]
  3. The efficacy measured by complete response rate (CRR) in Part II [ Time Frame: Up to 5 years ]
  4. The efficacy measured by partial response rate (PRR) in Part II [ Time Frame: Up to 5 years ]
  5. The efficacy measured by progression free survival (PFS) in Part II [ Time Frame: Up to 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Men and women with the age of 18-75 years
  • Subjects with B-cell lymphoma (defined by World Health Organization (WHO) classification) refractory or relapsed following at least one line of therapy
  • Judged by the investigator as requiring treatment.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Life expectancy of at least 4 months.
  • Adequate hematological function
  • Adequate renal function
  • Adequate liver function
  • Adequate Coagulation function
  • Female subjects of childbearing potential and non-sterile males must practice at least one of the following methods of birth control with partner(s) throughout the study and for 90 days after discontinuing study drug: total abstinence from sexual intercourse, double-barrier contraception, Intrauterine device (IUD) or hormonal contraceptive initiated at least 3 months prior to first dose of study drug.
  • Male subjects must not donate sperm from start of study drug administration, until 90 days after discontinuation of treatment.

Key Exclusion Criteria:

  • With Central Nervous System (CNS) involvement of the disease.
  • The pathological type of the disease has Disease transformation.
  • Has underdone allogeneic hematopoietic stem cell transplantation.
  • Has received corticosteroid anti-neoplastic treatment within 7 days before the first dose, has received radiotherapy and chemotherapy within 4 weeks before the first dose or has received treatment with monoclonal antibody within 4 weeks before the first dose.
  • Has received BTK inhibitor treatment prior to enrollment.
  • Has received chemotherapy and has not yet recovered from toxicity
  • Has received Chinese herbal medicine as anti-neoplastic therapy within 4 weeks before starting study treatment.
  • History of other malignancies within 2 years before study
  • With uncontrolled systemic infection.
  • Major surgery in the past 4 weeks.
  • With known HIV, or active hepatitis B or hepatitis C virus infection.
  • With cardiovascular disease of New York Heart Association (NYHA) Classification ≥ 3.
  • Significant ECG abnormalities
  • Significant active renal, neurologic, psychiatric, hepatic or endocrinologic disease that in the investigator's opinion would adversely impact on his/her participation in the study.
  • Inability to comply with study procedures.
  • Currently taking anticoagulant drugs.
  • Currently taking potent CYP3A inhibitor or inducer
  • Had stroke or cerebral hemorrhage within 6 months before enrollment.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03189524

Layout table for location information
China, Beijing
Beijing Cancer Hospital
Beijing, Beijing, China, 100142
China, Hubei
Tongji Hospital, Tongji Medical College Huazhong Univ of Sci and Tch
Wuhan, Hubei, China
China, Jiangsu
Jiangsu Province Hospital
Nanjing, Jiangsu, China
China, Tianjin
Tianjin Hematonosis Hospital
Tianjin, Tianjin, China
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Jun Zhu, PhD Beijing Cancer Hospital
Jun Zhu, BS, Jianyong Li, MD, Jianfeng Zhou, Yuqin Song, MD, Junyuan Qi, Wei Xu, Dengju Li, MD, Mingyuan Sun, Ling Xue, PhD, Liudi Yang, Yinwei Zhang, Lai Wang, PhD, Jane Huang, MD, Shibao Feng, PhD, Lugui Qiu, MD. BGB-3111, a Highly Specific BTK Inhibitor, Is Well Tolerated and Highly Active in Chinese Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 Trial in China. Blood. 2017; 130(1): 5347.

Layout table for additonal information
Responsible Party: BeiGene Identifier: NCT03189524    
Other Study ID Numbers: BGB-3111-1002
CTR20160204 ( Registry Identifier: Center for drug evaluation, CFDA )
First Posted: June 16, 2017    Key Record Dates
Last Update Posted: June 30, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action